,33,34 Our findings of rare damaging variants at IGF1R, and also at IGFALS and IGFBP3, indicate that reduced IGF-1 bioactivity and signaling increases risk for T2D. This evidence concerns the gene IGFBP3 and type 2 diabetes mellitus.